Table 5.
Phase I/II clinical trials with non-gene engineered T cells and other lymphocytes in glioblastoma.
| Clinical Trial | Phase | Lymphocytes | Other Treatment | Indication | # Patients | OR (%) | CR (%) | OS |
|---|---|---|---|---|---|---|---|---|
| 9390198 | I | Alloreactive CTLs | SS, IL-2 | R A, O grade III-IV |
5 | 0/5 (0) | 0/5 (0) | - |
| 24795429 | I | Autologous CMV-specific T cells | CT | R GB CMV seropositive |
11 | 0/11 (0) | 0/11 (0) | - |
|
NCT01588769 29511178 |
I | Autologous CTLs and NK cells | None | R GB | 10 | 3/10 (30) | 0/10 (0) | - |
| 9647171 | I | Autologous T lymphocytes | Irradiated tumor cell vaccination |
R A grade III-IV |
10 | 3/10 (30) | 0/10 (0) | - |
|
NCT00004024 16817692 |
II | Autologous T lymphocytes | Irradiated tumor cell vaccination |
R A or O grade II-IV |
19 | 8/19 (42) | 1/19 (5) | - |
| 10778730 | I | Autologous TILs | SS, IL-2 | R GB | 6 | 3/6 (50) | 1/6 (17) | - |
|
NCT00331526 19816190 |
II | Autologous LAK cells | SOC, IL-2 | P GB | 33 | NR | NR | 20.5 mo |
|
NCT00003067 8625188 |
I | Autologous LAK cells | SS, IL-2 | R GB R A grade III |
19 | 4/19 (21) | 2/19 (11) | - |
Abbreviations: SS, second surgical procedure; IL-2, interleukin 2; CT, chemotherapy; CTL, cytotoxic T lymphocyte; P, primary; R, recurrent; GB, glioblastoma; A, astrocytoma; O, oligodendroglioma; NR, not reported; OR, objective response; CR, complete response; both according to Response Assessment in Neuro-Oncology (RANO) criteria. Number of patients with responses = before dash. Total number of patients treated = after dash. Percentage of responses = between brackets (bold).